featured
Lapatinib in Combination With Foretinib in HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase-I Study of Lapatinib in Combination With Foretinib, a c-MET, AXL and Vascular Endothelial Growth Factor Receptor Inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Metastatic Breast Cancer
Breast Cancer Res 2017 May 02;[EPub Ahead of Print], SK Chia, SL Ellard, M Mates, S Welch, C Mihalcioiu, WH Miller, K Gelmon, C Lohrisch, V Kumar, S Taylor, L Hagerman, R Goodwin, T Wang, S Sakashita, MS Tsao, E Eisenhauer, P BradburyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.